Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT)
CUSIP: 71722W107
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 78,837,943
- Total 13F shares
- 57,415,787
- Share change
- -6,611,090
- Total reported value
- $550,618,405
- Put/Call ratio
- 77%
- Price per share
- $9.59
- Number of holders
- 117
- Value change
- -$26,654,537
- Number of buys
- 59
- Number of sells
- 73
Quarterly Holders Quick Answers
What is CUSIP 71722W107?
CUSIP 71722W107 identifies PHAT - Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 71722W107:
Top shareholders of PHAT - Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
13%
|
10,109,279
|
$63,385,179 | — | 31 Mar 2025 | |
| Medicxi Ventures Management (Jersey) Ltd |
3/4/5
13F
|
10%+ Owner · Company |
9.5%
from 13F
|
7,464,572
|
$60,463,034 | — | 24 Jan 2024 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
8.9%
|
7,042,325
|
$44,155,377 | — | 31 Mar 2025 | |
| TAKEDA PHARMACEUTICAL CO LTD |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,755,583
|
$30,420,222 | — | 24 Jan 2024 | |
| Invesco Ltd. |
13F
|
Company |
4.6%
|
3,650,812
|
$22,890,591 | — | 31 Mar 2025 | |
| Carlyle Group Inc. |
13F
|
Company |
4.4%
|
3,496,808
|
$21,924,986 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
4.6%
from 13D/G
|
3,323,603
|
$20,838,990 | — | 31 Mar 2025 | |
| James N. Topper |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
5,950,827
mixed-class rows
|
$19,639,309 | +$14,609 | 03 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.5%
|
2,778,687
|
$17,422,368 | — | 31 Mar 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
3.2%
|
2,514,284
|
$15,764,561 | — | 31 Mar 2025 | |
| NEA Management Company, LLC |
13F
|
Company |
2.5%
|
1,960,169
|
$12,290,260 | — | 31 Mar 2025 | |
| David A. Socks |
3/4/5
|
Director |
—
mixed-class rows
|
1,248,756
mixed-class rows
|
$11,216,740 | — | 23 May 2024 | |
| WASATCH ADVISORS LP |
13F
|
Company |
2.2%
|
1,701,627
|
$10,669,201 | — | 31 Mar 2025 | |
| Azmi Nabulsi |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
1,406,436
mixed-class rows
|
$10,029,637 | — | 27 Feb 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
1.8%
|
1,445,000
|
$9,060,150 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.5%
|
1,200,000
|
$7,524,000 | — | 31 Mar 2025 | |
| Catalys Pacific, LLC |
13F
|
Company |
1.5%
|
1,167,114
|
$7,317,805 | — | 31 Mar 2025 | |
| Propel Bio Management, LLC |
13F
|
Company |
1.4%
|
1,134,927
|
$7,115,992 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.4%
|
1,131,032
|
$7,091,571 | — | 31 Mar 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
1.4%
|
1,104,308
|
$6,924,000 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
1,016,423
|
$6,374,314 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.1%
|
901,354
|
$5,651,490 | — | 31 Mar 2025 | |
| Avidity Partners Management LP |
13F
|
Company |
1%
|
800,000
|
$5,016,000 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.95%
|
751,692
|
$4,713,109 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.9%
|
707,578
|
$4,436,514 | — | 31 Mar 2025 | |
| Simplify Asset Management Inc. |
13F
|
Company |
0.86%
|
681,935
|
$4,275,732 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.76%
|
596,108
|
$3,737,597 | — | 31 Mar 2025 | |
| PRUDENTIAL FINANCIAL INC |
13F
13D/G
|
Company |
0%
from 13D/G
|
568,630
|
$3,565,310 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.67%
|
530,859
|
$3,328,486 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.66%
|
523,363
|
$3,281,486 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.65%
|
509,582
|
$3,195,079 | — | 31 Mar 2025 | |
| StepStone Group LP |
13F
|
Company |
0.54%
|
422,085
|
$2,646,473 | — | 31 Mar 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.51%
|
398,751
|
$2,500,169 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.49%
|
386,623
|
$2,424,127 | — | 31 Mar 2025 | |
| Terrie Curran |
3/4/5
|
President and Chief Executive, Director |
—
mixed-class rows
|
706,805
mixed-class rows
|
$2,399,933 | — | 27 Feb 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.44%
|
348,035
|
$2,182,179 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.4%
|
314,873
|
$1,974,253 | — | 31 Mar 2025 | |
| Molly Henderson |
3/4/5
|
CFO and CBO |
—
mixed-class rows
|
244,542
mixed-class rows
|
$1,558,384 | — | 07 Apr 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.25%
|
200,690
|
$1,258,326 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.24%
|
187,874
|
$1,177,970 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.23%
|
179,721
|
$1,126,850 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.22%
|
170,281
|
$1,067,661 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.2%
|
161,138
|
$1,010,335 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.17%
|
137,393
|
$861,454 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
114,535
|
$718,137 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.14%
|
107,399
|
$673,392 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.13%
|
101,520
|
$636,530 | — | 31 Mar 2025 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.13%
|
99,776
|
$625,596 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.13%
|
99,744
|
$625,395 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.12%
|
97,327
|
$610,240 | — | 31 Mar 2025 |
Institutional Holders of Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) as of Q2 2025
As of 30 Jun 2025,
Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) was held by
117 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
57,415,787 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Invesco Ltd., Carlyle Group Inc., BlackRock, Inc., VANGUARD GROUP INC, Ensign Peak Advisors, Inc, MILLENNIUM MANAGEMENT LLC, 683 Capital Management, LLC, and NEA Management Company, LLC.
This page lists
116
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
136
Q2 2025 holders
117
Holder diff
-19
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.